(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.72%.
Mbx Biosciences's earnings in 2026 is -$86,608,000.On average, 12 Wall Street analysts forecast MBX's earnings for 2026 to be -$136,343,142, with the lowest MBX earnings forecast at -$151,131,696, and the highest MBX earnings forecast at -$115,947,598. On average, 12 Wall Street analysts forecast MBX's earnings for 2027 to be -$176,248,916, with the lowest MBX earnings forecast at -$188,448,165, and the highest MBX earnings forecast at -$149,032,645.
In 2028, MBX is forecast to generate -$193,041,327 in earnings, with the lowest earnings forecast at -$254,218,440 and the highest earnings forecast at -$80,963,409.